Tag: Adaptive Immunity

Non-AUG HIV-1 uORF translation elicits specific T cell immune response and regulates viral transcript expression

Abstract Human immunodeficiency virus type-1 (HIV-1) is a complex retrovirus that relies on alternative splicing, translational, and post-translational mechanisms to produce over 15 functional proteins from its single ~10 kb transcriptional unit. Using ribosome profiling, nascent protein labeling, RNA sequencing, and whole-proteomics of infected CD4 + T lymphocytes, we characterized the transcriptional, translational, and post-translational landscape during infection.… Continue reading Non-AUG HIV-1 uORF translation elicits specific T cell immune response and regulates viral transcript expression

Functional signatures and activation mechanisms of effector γδ T cell subsets

Genome-wide transcriptomics analysis of IFNγ-producing or IL-17A-producing γδ T cell subpopulations reveals marked differences in their mode of activation and functional potential in the periphery. We describe the differential expression of a set of 20 signature genes in models of infection and autoimmunity that may be useful for future studies on γδ T cell functions.… Continue reading Functional signatures and activation mechanisms of effector γδ T cell subsets

Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma

Abstract CD19-targeted chimeric antigen receptor (CAR) T cells have provided a breakthrough in the treatment of patients with relapsed and/or refractory large B cell lymphoma (LBCL). Currently, three CD19-targeted CAR T cell products are approved by the FDA and various other regulators for the treatment of patients with LBCL: axicabtagene ciloleucel, tisagenlecleucel and lisocabtagene maraleucel.… Continue reading Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma

Towards more efficient synthetic immunomodulators: biological characterization and mechanism of action of monosaccharide-derived TLR4 agonists

Toll-like receptors (TLRs), including TLR4, play a crucial role in innate immunity activation, and small molecular TLR4 activators (agonists) are in preclinical and clinical phase of development as vaccine adjuvant or tumor immunotherapeuutics. .Recently, we have generated novel glucosamine-derived compounds, FP molecules, that are active as TLR4 agonists. Despite their chemical structure different from LPS,… Continue reading Towards more efficient synthetic immunomodulators: biological characterization and mechanism of action of monosaccharide-derived TLR4 agonists

TWiV 1193: HPV or not to B

TWiV reviews a facility accident that killed monkeys, new bird blu genotype found in Nevada dairy cattle, Argentina plans to leave WHO, yellow fever on the rise, dynamics of HPV infections in women, and Epstein-Barr virus protein targets B cell receptor for degradation. Hosts: Vincent Racaniello, Alan Dove, and Angela Mingarelli Click arrow to playDownload TWiV… Continue reading TWiV 1193: HPV or not to B

TWiV 1192: Clinical update with Dr. Daniel Griffin

In his weekly clinical update, Dr. Griffin and Vincent Racaniello discuss confirmation of Robert F Kennedy as HHS sectary, mpox, Ebola, how the American people support vaccine development and administration, the measles outbreak in the US-Texas, Georgia and influenza: the number of human infections, high avian flu in mammals, house cats and dairy cows before… Continue reading TWiV 1192: Clinical update with Dr. Daniel Griffin